z-logo
open-access-imgOpen Access
Human DNA ligase IV is able to use NAD+ as an alternative adenylation donor for DNA ends ligation
Author(s) -
Shih-Hsun Chen,
Xiaochun Yu
Publication year - 2018
Publication title -
nucleic acids research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 9.008
H-Index - 537
eISSN - 1362-4954
pISSN - 0305-1048
DOI - 10.1093/nar/gky1202
Subject(s) - dna ligase , dna ligases , biology , nad+ kinase , dna polymerase mu , dna repair , microbiology and biotechnology , biochemistry , dna , ubiquitin ligase , ligation , adenylylation , okazaki fragments , dna polymerase , ubiquitin , enzyme , eukaryotic dna replication , circular bacterial chromosome , biosynthesis , gene
All the eukaryotic DNA ligases are known to use adenosine triphosphate (ATP) for DNA ligation. Here, we report that human DNA ligase IV, a key enzyme in DNA double-strand break (DSB) repair, is able to use NAD+ as a substrate for double-stranded DNA ligation. In the in vitro ligation assays, we show that the recombinant Ligase IV can use both ATP and NAD+ for DNA ligation. For NAD+-mediated ligation, the BRCA1 C-terminal (BRCT) domain of Ligase IV recognizes NAD+ and facilitates the adenylation of Ligase IV, the first step of ligation. Although XRCC4, the functional partner of Ligase IV, is not required for the NAD+-mediated adenylation, it regulates the transfer of AMP moiety from Ligase IV to the DNA end. Moreover, cancer-associated mutation in the BRCT domain of Ligase IV disrupts the interaction with NAD+, thus abolishes the NAD+-mediated adenylation of Ligase IV and DSB ligation. Disrupting the NAD+ recognition site in the BRCT domain impairs non-homologous end joining (NHEJ) in cell. Taken together, our study reveals that in addition to ATP, Ligase IV may use NAD+ as an alternative adenylation donor for NHEJ repair and maintaining genomic stability.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here